• About us
• Contact

Advertisement

Organisation › Details

Celgene Corporation (Nasdaq: CELG)

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. *

 

	Start	1986-01-01 splitoff
	Group	Bristol Myers Squibb (BMS) (Group)
	Predecessor	Celanese (Group)
	Industry	pharmaceutical
	Industry 2	cancer drug
	Street	86 Morris Avenue
	City	07901 Summit, NJ
	Tel	+1-908-673-9000
		Address record changed: 2020-12-02
Basic data	Employees	n. a.
	Currency	USD
	Annual sales	898,873,000 (revenue, total, consolidated (2006) 2006-12-31)
	Profit	68,981,000 (2006-12-31)
	Cash	1,982,210,000 (2006-12-31)
		* Document for »About Section«:
		Record changed: 2023-07-10

Advertisement

More documents for Bristol Myers Squibb (BMS) (Group)

• [1] ITM Isotope Technologies Munich SE. (6/20/24). "Press Release: ITM Appoints Dr. Andrew Cavey as CEO to Lead Organization in its Next Stage of Growth". Garching....
• [2] Evotec SE. (6/12/24). "Press Release: Evotec Announces Progress in Neuroscience Collaboration with Bristol Myers Squibb". Hamburg....
• [3] VantAI. (2/13/24). "Press Release: VantAI Enters Collaboration With Bristol Myers Squibb to Accelerate Molecular Glue Drug Discovery Through Artificial Intelligence". New York, NY....
• [4] GlycoEra AG. (1/5/24). "Press Release: GlycoEra AG Announces New Investor, Appoints Industry Veteran Greg Fralish as Chief Business Officer". Newton, MA & Wädenswil....
• [5] Bristol Myers Squibb Company. (12/26/23). "Press Release: Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio". Princeton, NJ & San Diego, CA....
• [6] Bristol Myers Squibb Company. (12/22/23). "Press Release: Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics". Princeton, N.J. & Boston, MA....
• [7] Armstrong, Annalee / Bayer, Max / Masson, Gabrielle [Fierce Biotech]. (12/22/23). "News: Fierce Biotech M&A Tracker 2023. BMS, AbbVie Drop Billions for Neuropsychiatry Biotechs"....
• [8] RayzeBio, Inc.. (9/19/23). "Press Release: RayzeBio, Inc. Announces Closing of Upsized $358 Million Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares". San Diego, CA....
• [9] RayzeBio, Inc.. (9/14/23). "Press Release: RayzeBio, Inc. Announces Pricing of Upsized $311 Million Initial Public Offering". San Diego, CA....
• [10] Immatics N.V.. (7/24/23). "Press Release: Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb". Tübingen & Houston, TX....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.